Hormonal
Exenatide (AC2993) administered subcutaneously twice or thrice daily for 28 days significantly reduces HbA1c and postprandial glucose in patients with type 2 diabetes who are inadequately controlled on metformin and/or sulfonylureas.
If you have type 2 diabetes and your current pills aren't keeping your blood sugar in range, adding exenatide (a GLP-1 based injection) can significantly lower your HbA1c and post-meal blood sugar spikes over a short period. It works by boosting insulin when needed, lowering glucagon, and slowing digestion. While it might cause some initial nausea, this often improves. Importantly, it does not cause weight gain, unlike some other diabetes medications.
All AC2993 groups had reductions in HbA1c ranging from 0.7 to 1.1% (P < 0.006)... AC2993 treatment led to statistically significant (P < 0.004) reductions in serum fructosamine... Statistically significant reductions (P < 0.004) from baseline to day 28 in mean postprandial plasma glucose concentration were observed with AC2993 treatment
Why this rating
Randomized, triple-blind, placebo-controlled trial with 109 patients, though short duration (28 days).
Source
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes
Mark Fineman et al. · Diabetes Care · 2003
DOI 10.2337/diacare.26.8.2370
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →